Reviewing vitiligo expectations, Phase 3 readout CY25CUV are conducting two Phase 3 trials to expand the label of Scenesse to include patients with vitiligo.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.